Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028
Summary
Gilead has raised its sales projection for the year 2026. Additionally, the company announced that the price of its drug Biktarvy will be reduced by 38 percent under Medicare beginning in 2028.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.